Upharmacia February 2017
PHARMA COMPANIES
NEWS
MSD to
S upply F irst
I mmuno -O n -
cology D rug in U kraine
American pharmaceutical
company MSD plans to supply
to Ukraine first immuno-
oncology drug KEYTRUDA ®
(pembrolizumab) by the end
of Apr 2017. The drug was
registered in Ukraine in Oct
2016 within the simplified
registration procedure.
KEYTRUDA ® is used for the
treatment of different kind of
cancer like advanced melanoma
and non-small cell lung cancer
(NSCLC).
In Ukraine, the drug will be
available in bottle form 100 mg,
its price amounts USD 4 ths per
unit.
“The high cost of the drugs
casts doubt on its inclusion
in the nomenclature of public
procurements”, the Head
of innovation medicines
department of MSD Ukraine
said. “Even so, the company is
ready to communicate with the
government to increase the
access of more patients to this
therapy.”
A ntimonopoly
C ommittee
to I nvestigate P ossible
M onopolization of the
U krainian M arket by D arnitsa
Antimonopoly Committee
6
of Ukraine started the legal
investigation on possible
concentration of Ukrainian
pharmaceutical market by
Darnitsa company through
the acquisition of share of
Borshchahivskiy Chemical
Pharmaceutical Plant (BCPP).
After the acquisition of more
than 50% of BCPP’s shares,
the concentration may occur
on the markets of drugs,
which affect alimentary,
cardiovascular, nervous and
respiratory systems, blood and
blood forming organs, a